查詢結果分析
相關文獻
- The Clinical Significance of Pre-treatment Glasgow Prognostic Score (GPS) in Metastatic Colorectal Cancer (mCRC) Patients with FOLFIRI Plus Cetuximab or Bevacizumab as First-line Treatment: A Single Institutional Analysis
- Treatment of Metastatic Colorectal Adenocarcinoma with Fluorouracil and High-Dose Leucovorin : A Pilot Study
- Oxaliplatin in Combination with 5-Fluorouracil and Leucovorin as Second-Line Therapy for Metastatic Colorectal Cancer
- Regorafenib:轉移性大腸直腸癌與胃腸道基質瘤之口服標靶藥物
- Efficacy and Safety of Two Different Regimens of Irinotecan for Metastatic Colorectal Cancer: Experience in a Southern Taiwan Medical Center
- Hepatitis B and/or Hepatitis C Infection Does Not Influence Survival Rate among Patients with Metastatic Colorectal Cancer
- Gastrointestinal Perforation in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin)--Three Cases Report
- Perforated Duodenal Ulcer with Blurred Peritonitis in a Colorectal Cancer Patient with Liver Metastasis
- Analysis of Prognostic Factors in Chinese Women with Breast Cancer in Southern Taiwan
- Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4) in Metastatic Colorectal Cancer (CRC)
頁籤選單縮合
題 名 | The Clinical Significance of Pre-treatment Glasgow Prognostic Score (GPS) in Metastatic Colorectal Cancer (mCRC) Patients with FOLFIRI Plus Cetuximab or Bevacizumab as First-line Treatment: A Single Institutional Analysis=治療前格拉斯哥預後評分在以Cetuximab或Bevacizumab加上FOLFIRI為第一線治療的轉移性結直腸癌患者的臨床意義--單一機構分析 |
---|---|
作 者 | 楊博翔; 蔡祥麟; 黃敬文; 蘇偉智; 王照元; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷 期 | 34:4 2023.12[民112.12] |
頁 次 | 頁239-247 |
分類號 | 416.245 |
關鍵詞 | 治療前格拉斯哥預後評分; 轉移性大腸直腸癌; 整體存活率; 無疾病進展存活率; 轉移病灶切除率; Pre-treatment Glasgow prognostic score; GPS; Metastatic colorectal cancer; mCRC; Overall survival; OS; Progression-free survival; PFS; Metastasectomy rates; |
語 文 | 英文(English) |